SpringerProtocols: Abstract: Virus-like Particles: A Novel Tool for the Induction and Monitoring of Both T-Helper and Cytotoxic T-Lymphocyte Activity

Virus-like Particles: A Novel Tool for the Induction and Monitoring of Both T-Helper and Cytotoxic T-Lymphocyte Activity

By: Ludwig Deml³, Jens Wild³, Ralf Wagner³

Abstract

Full Text

Download PDF (457K)

T-cells play a crucial role in the control of various viral infections such as HIV and herpes viruses. Thus, the development of advanced techniques for the stimulation and measurement of both antigen-specific T-helper and CTL responses is one of most meaningful objectives in vaccinology. Herein, we present HIV-1 Pr55^gag lipoprotein particles (VLPs) to be a potent antigen for introducing epitopes into the MHC-class-I and -II processing and presentation pathway. These VLPs can easily be produced in insect cells by using the baculovirus expression system. Immunization studies in mice revealed the strong capacity of these VLPs to stimulate Gag-specific T-helper-1 cell-biased humoral and cellular immune responses. In addition, these VLPs can be used as a stimulator antigen for the detection of Gag-specific T-helper and CTL responses, as determined by conventional ELISA, ELISpot, FACS, and ⁵¹Cr-release assays. These results strongly underline the value of VLPs as a stimulator of MHC-class-I and -II mediated epitope presentation for preventive, therapeutic, and diagnostic purposes.

Affiliation(s): (3) Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

Book Title: Molecular Diagnosis of Infectious Diseases

Series: Methods in Molecular Medicine | Volume: 94 | Pub. Date: Dec-01-2003 | Page Range: 133-157 | DOI: 10.1385/1-59259-679-7:133

Subject: Infectious Diseases

References

Download References

1.	Rook, A. H. (1988) Interactions of cytomegalovirus with the human immune system. Rev. Infect. Dis. 10, 460–467.

2.	Arvin, A. M. (1992) Cell-mediated immunity to varicella-zoster virus. J. Infect. Dis. 166, 35–41.

3.	Simmons, A. and Tscharke, D. C. (1992) Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J. Exp. Med. 175, 1337–1344.

4.	Gotch, F., Gallimore, A., and McMichael, A. (1996) Cytotoxic T cells—protection from disease progression—protection from infection. Immunol. Lett. 51, 125–128.

5.	Khanna, R., Moss, D. J., and Burrows, S. R. (1999) Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170, 49–64.

6.	Khanna, R. and Burrows, S. R. (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54, 19–48.

7.	Pantaleo, G., Demarest, J. F., Soudeyns, H., et al. (1994) Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370, 463–467.

8.	Koup, R. A., Safrit, J. T., Cao, Y., et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655.

9.	Rinaldo, C., Huang, X. L., Fan, Z. F., et al. (1995) High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69, 5838–5842.

10.	Koup, R. A. and Ho, D. D. (1994) Shutting down HIV. Nature 370, 416.

11.	Safrit, J. T., Andrews, C. A., Zhu, T., Ho, D. D., and Koup, R. A. (1994) Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. J. Exp. Med. 179, 463–472.

12.	Klein, M., Van Baalen, C., Holwerda, A., et al. (1995) Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181, 1365–1372.

13.	Betts, M. R., Krowka, J., Santamaria, C., et al. (1997) Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J. Virol. 71, 8908–8911.

14.	Durali, D., Morvan, J., Letourneur, F., et al. (1998) Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J. Virol. 72, 3547–3553.

15.	Lynch, J. A., deSouza, M., Robb, M. D., et al. (1998) Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J. Infect. Dis. 178, 1040–1046.

16.	Wagner, R., Leschonsky, B., Harrer, E., et al. (1999) Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 162, 3727–3734.

17.	Cox, J. C. and Coulter, A. R. (1997) Adjuvants—a classification and review of their modes of action. Vaccine 15, 248–256.

18.	Gustafson, G. L. and Rhodes, M. J. (1992) Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143, 483–488.

19.	Wu, J. Y., Gardner, B. H., Murphy, C. I., et al. (1992) Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 148, 1519–1525.

20.	Ke, Y., Li, Y., and Kapp, J. A. (1995) Ovalbumin injected with complete Freund’s adjuvant stimulates cytolytic responses. Eur. J. Immunol. 25, 549–553.

21.	Schulz, M., Zinkernagel, R. M., and Hengartner, H. (1991) Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88, 991–993.

22.	Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R. N., and Berzofsky, J. A. (1990) Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344, 873–875.

23.	Zhou, F., Rouse, B. T., and Huang, L. (1992) Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. 52, 6287–6291.

24.	Maloy, K. J., Donachie, A. M., O’Hagan, D. T., and Mowat, A. M. (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81, 661–667.

25.	VanCott, T. C., Kaminski, R. W., Mascola, J. R., et al. (1998) HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160, 2000–2012.

26.	von Brunn, A., Fruh, K., Muller, H. M., Zentgraf, H. W., and Bujard, H. (1991) Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine 9, 477–484.

27.	Schlienger, K., Mancini, M., Riviere, Y., Dormont, D., Tiollais, P., and Michel, M. L. (1992) Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66, 2570–2576.

28.	Michel, M. L., Mancini, M., Schlienger, K., and Tiollais, P. (1993) Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Res. Virol. 144, 263–267.

29.	Schirmbeck, R., Melber, K., Kuhrober, A., Janowicz, Z. A., and Reimann, J. (1994) Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J. Immunol. 152, 1110–1113.

30.	Breitburd, F., Kirnbauer, R., Hubbert, N. L., et al. (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959–3963.

31.	Kirnbauer, R. (1996) Papillomavirus-like particles for serology and vaccine development. Intervirology 39, 54–61.

32.	Sedlik, C., Saron, M., Sarraseca, J., Casal, I., and Leclerc, C. (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA 94, 7503–7508.

33.	Lo-Man, R., Rueda, P., Sedlik, C., Deriaud, E., Casal, I., and Leclerc, C. (1998) A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur. J. Immunol. 28, 1401–1407.

34.	Griffiths, J. C., Berrie, E. L., Holdsworth, L. N., et al. (1991) Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. J. Virol. 65, 450–456.

35.	Harris, S. J., Gearing, A. J., Layton, G. T., Adams, S. E., and Kingsman, A. J. (1992) Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3∶Ty virus-like particles. Immunology 77, 315–321.

36.	Delchambre, M., Gheysen, D., Thines, D., et al. (1989) The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 8, 2653–2660.

37.	Wills, J. W. and Craven, R. C. (1991) Form, function, and use of retroviral gag proteins. AIDS 5, 639–654.

38.	Gheysen, D., Jacobs, E., de Foresta, F., et al. (1989) Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59, 103–112.

39.	Vernon, S. K., Murthy, S., Wilhelm, J., et al. (1991) Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system. J. Gen. Virol. 72, 1243–1251.

40.	Royer, M., Cerutti, M., Gay, B., Hong, S. S., Devauchelle, G., and Boulanger, P. (1991) Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology 184, 417–422.

41.	Wagner, R., Fliessbach, H., Wanner, G., et al. (1992) Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127, 117–137.

42.	Wagner, R., Deml, L., Schirmbeck, R., Niedrig, M., Reimann, J., and Wolf, H. (1996) Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220, 128–140.

43.	Deml, L., Schirmbeck, R., Reimann, J., Wolf, H., and Wagner, R. (1997) Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235, 26–39.

44.	Wolf, H., Modrow, S., Soutschek, E., Motz, M., Grunow, R., and Döbl, H. (1990) Production, mapping and biological characterisation of monoclonal antibodies to the core protein (p24) of the human immunodeficiency virus type 1. AIFO 1, 24–29.

45.	Deml, L., Kratochwil, G., Osterrieder, N., Knuchel, R., Wolf, H., and Wagner, R. (1997) Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 235, 10–25.

46.	Wagner, R., Teeuwsen, V. J., Deml, L., et al. (1998) Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 245, 65–74.

47.	Paliard, X., Liu, Y., Wagner, R., Wolf, H., Baenziger, J., and Walker, C. M. (2000) Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum Retroviruses 16, 273–282.

48.	Ogg, G. S., Jin, X., Bonhoeffer, S., et al. (1998) Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103–2106.

49.	Betts, M. R., Casazza, J. P., Patterson, B. A., et al. (2000) Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J. Virol. 74, 9144–9151.

50.	Zajac, A. J., Murali-Krishna, K., Blattman, J. N., and Ahmed, R. (1998) Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10, 444–449.

51.	Waldrop, S. L., Pitcher, C. J., Peterson, D. M., Maino, V. C., and Picker, L. J. (1997) Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99, 1739–1750.

52.	Sester, M., Sester, U., Kohler, H., et al. (2000) Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS 14, 2653–2668.

53.	Heintel, T., Sester, M., Rodriguez, M. M., et al. (2002) The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS 16, 1497–1501.

54.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

55.	Qiu, J. T., Song, R., Dettenhofer, M., et al. (1999) Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73, 9145–9152.

56.	Takahashi, H., Cohen, J., Hosmalin, A., et al. (1988) An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85, 3105–3109.

57.	White, B. A. (1993) Methods in Molecular Biology: PCR Protocols, Current Methods and Applications. Humana, Totowa, NJ.

Comments (Loading...)

Post comment/View all comments